Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.95 USD
Change Today +0.045 / 5.00%
Volume 135.6K
As of 5:20 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/12/15 - $1.97
52 Week Low
11/11/15 - $0.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 for patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

13 Employees
Last Reported Date: 03/30/15
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Scientific Officer and Director
Total Annual Compensation: $447.2K
Compensation as of Fiscal Year 2014.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

OXiGENE, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, loss from operations was $3,599,000 against $3,453,000 a year ago. Net loss and comprehensive loss was $3,592,000 against $3,450,000 a year ago. Basic and diluted net loss per common share attributable to common stock was $0.14 against $0.17 a year ago. For the nine months, loss from operations was $9,704,000 against $10,005,000 a year ago. Net loss and comprehensive loss was $9,688,000 against $10,009,000 a year ago. Basic and diluted net loss per common share attributable to common stock was $0.39 against $0.64 a year ago.

OXiGENE, Inc. Announces Positive Initial Data from Phase 1B Study of CA4P in Combination with Pazopanib in Patients with Advanced Recurrent Ovarian Cancer

OXiGENE, Inc. announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient (pazopanib) in patients with advanced recurrent ovarian cancer. The data are from the ongoing 'PAZOFOS' study and were presented at the nineteenth International Meeting of the European Society of Gynaecological Oncology (ESGO) in Nice, France. Dr. Rustin reported that twelve patients have been enrolled in the phase 1b portion of the study. Nine of the patients were evaluated for objective response using RECIST criteria, showing two partial responses, five stable diseases and two progressive diseases. Eight of the ten patients with evaluable data demonstrated decreases in the tumor marker CA125, with three achieving a response according to CGIC criteria. Dr. Rustin also noted that four patients were still on treatment, and that the efficacy data are currently preliminary and unverified. Safety data showed that the combination of CA4P and pazopanib was generally well tolerated with no Grade 4-5 adverse events (AEs). The most commonly reported AEs were hypertension, fatigue, and pain. The Development Safety Update Report #1 submitted to the regulatory body stated that no definitive conclusions can be made regarding the benefit of treatment in the small subset of patients treated so far. PAZOFOS is a randomized, controlled clinical study consisting of a phase 1b dose escalation portion (CA4P plus pazopanib) and a phase 2 portion comparing CA4P plus pazopanib versus pazopanib alone. The study is designed to enroll up to 128 patients at up to ten sites in the United Kingdom. The primary endpoint for the phase 2 portion is progression-free survival; secondary endpoints include safety, overall survival, objective response rate and relevant biomarkers.

OXiGENE, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia

OXiGENE, Inc. announced that it has initiated a phase 1b/2 clinical trial (Study OX1222) of its investigational drug OXi4503 for treatment of acute myeloid leukemia (AML). OXi4503, which has shown significant activity in preclinical studies of AML, is a novel VDA that is designed to reduce blood flow to tumors and to prevent cancer cells from replicating. Study OX1222 is a continuation and expansion of a phase 1 single site clinical trial of OXi4503 conducted by the University of Florida (UF) with support from the Leukemia & Lymphoma Society. OXiGENE is expanding upon the UF study to speed collection of additional safety and efficacy data and to obtain clinical data for OXi4503 in combination with cytarabine, which is an approved treatment for AML.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $0.95 USD +0.045

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OXIGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at